Overview

Our pipeline includes clinical-stage drug candidates each with its own unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors.

Voruciclib
Oral CDK9 Inhibitor

Voruciclib, a selective, orally administered, inhibitor of cyclin-dependent kinase 9 (CDK9) with potential to treat both hematological malignancies and solid tumors. It is in clinical development for patients with relapsed or refractory acute myeloid leukemia. Studies in solid tumors are also being considered.

INVESTIGATIONAL AGENTS THERAPEUTIC AREA COMBINATION PRE-IND PHASE 1/1B PHASE 1/2 Info
Commercial Rights:

Acute Myeloid Leukemia

Relapsed/refractory (2L+)
Single-agent VENCLEXTA®
(venetoclax)		 Completed Ongoing Info

Solid Tumors*

 Single-agent & Vemurafenib Completed Info

Voruciclib is an orally administered CDK9 inhibitor. Inhibition of CDK9 blocks the production of MCL1, an established resistance mechanism to the BCL2 inhibitor venetoclax. CDK9 also inhibits MYC, a transcription factor regulating cell proliferation and growth that has also been implicated in KRAS mutant tumors. This Phase 1b trial is evaluating voruciclib dose and schedule in patients with acute myeloid leukemia and B-cell malignancies.

We are evaluating the dose and schedule of voruciclib as a single-agent and in combination venetoclax, initially in patients with AML and subsequently across multiple indications.

Enrollment Status
AML: Ongoing
B-Cell Malignancies: Ongoing

Publications Clinical Trials

*Three Phase 1 Studies in a total of 77 patients. 

Patients & Caregivers
Learn More

Patients & Caregivers

Our driving purpose and principle is simple: deliver novel and differentiated cancer therapies that provide improved outcomes for patients.
Learn More